Cardiovascular update on TZDs

Wilson, Peter W. F.
June 2008
Cardiology Today;Jun2008, Vol. 11 Issue 6, p43
The article offers cardiovascular update on the favorable effects of thiazolidinediones (TZDs) on metabolism. It is said that the general action is by means of peroxisome-proliferator-activated receptor (PPAR) gamma and metabolic changes include lowering of plasma glucose, improved insulin sensitivity, and reduction in microalbuminuria. It is mentioned, however, that safety has been a concern with these medications since they were first used in the Primary Prevention of Diabetes trial.


Related Articles

  • PPARd Activity in Cardiovascular Diseases: A Potential Pharmacological Target. Tesse, Angela; Andriantsitohaina, Ramaroson; Ragot, Thierry // PPAR Research;2009, Special section p1 

    Activation of peroxisome proliferator-activated receptors (PPARs), and particularly of PPARa and PPAR?, using selective agonists, is currently used in the treatment of metabolic diseases such as hypertriglyceridemia and type 2 diabetes mellitus. PPARa and PPAR? anti-inflammatory,...

  • Pharmacological Regulation of Dyslipoproteinaemia in Insulin Resistant States. Chan, Dick C.; Watts, Gerald F. // Current Vascular Pharmacology;Jan2008, Vol. 6 Issue 1, p67 

    Dyslipidaemia is a common and consistent abnormality in insulin resistant subjects with obesity and type 2 diabetes mellitus associated with increased risk of cardiovascular disease. Lipoprotein metabolism is complex and abnormal plasma concentrations can result from alterations in the rates of...

  • The PPARα-PGC-1α Axis Controls Cardiac Energy Metabolism in Healthy and Diseased Myocardium. Duncan, Jennifer G.; Finck, Brian N. // PPAR Research;1/2/2008, Special section p1 

    The mammalian myocardium is an omnivorous organ that relies on multiple substrates in order to fulfill its tremendous energy demands. Cardiac energy metabolism preference is regulated at several critical points, including at the level of gene transcription. Emerging evidence indicates that the...

  • From Surface to Nuclear Receptors: The Endocannabinoid Family Extends its Assets. Pistis, M.; Melis, M. // Current Medicinal Chemistry;May2010, Vol. 17 Issue 14, p1450 

    Peroxisome proliferator-activated receptors (PPARs) have long been known as mediators of several physiological functions, among which the best characterized are lipid metabolism, energy balance and anti-inflammation. Their rather large and promiscuous ligand binding site has been recently...

  • A Tailored Therapy for the Metabolic Syndrome.  // Diabetes;Apr2002, Vol. 51 Issue 4, p1083 

    Presents a tailored therapy for the metabolic syndrome. Development of nonthiazolidinedione dual peroxisome proliferator-activated receptor agonist; Enhancement of insulin sensitivity; Improvement of primary cardiovascular risk factors.

  • PPAR-γ in the Cardiovascular System. Sheng Zhong Duan; Ivashchenko, Christine Y.; Usher, Michael G.; Mortensen, Richard M. // PPAR Research;1/2/2008, Special section p1 

    Peroxisome proliferator-activated receptor-γ (PPAR-γ), an essential transcriptional mediator of adipogenesis, lipid metabolism, insulin sensitivity, and glucose homeostasis, is increasingly recognized as a key player in inflammatory cells and in cardiovascular diseases (CVD) such as...

  • Rimonabant: profile report.  // Drugs & Therapy Perspectives;Apr2007, Vol. 23 Issue 4, p4 

    Adapted and reproduced from Drugs 2006; 66 (16): 2109-21[1-3]

  • PPARγ agonists do not directly enhance basal or insulin-stimulated Na+ transport via the epithelial Na+ channel. Nofziger, Charity; Chen, Lihong; Shane, Michael Anne; Smith, Chari D.; Brown, Kathleen K.; Blazer-Yost, Bonnie L. // Pflugers Archiv European Journal of Physiology;Dec2005, Vol. 451 Issue 3, p445 

    Selective agonists of peroxisome proliferator-activated receptor gamma (PPARγ) are anti-diabetic drugs that enhance cellular responsiveness to insulin. However, in some patients, fluid retention, plasma volume expansion, and edema have been observed. It is well established that insulin...

  • Physical activity in prevention and treatment of the metabolic syndrome. Lakka, Timo A.; Laaksonen, David E. // Applied Physiology, Nutrition & Metabolism;Feb2007, Vol. 32 Issue 1, p76 

    Randomised controlled trials have shown that exercise training has a mild or moderate favourable effect on many metabolic and cardiovascular risk factors that constitute or are related to the metabolic syndrome (MetS). Epidemiological studies suggest that regular physical activity prevents type...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics